Twenty years ago in a doctor’s office in Vancouver, Jeff and Megan Carroll faced a moment that upended their lives. An envelope held the result of a test showing how many times the DNA sequence “CAG” repeats in one of Jeff’s genes: too many repeats would confirm Huntington’s disease. Jeff’s mother had suffered from the fatal neurodegenerative disorder, and he had a 50 percent chance of inheriting the same mutation. When Megan shifted her gaze from the doctor to her husband, their plans for a family and a long life together suddenly dimmed.
The doctor asked them one last time if they really wanted to open the envelope. Rather than collapse under the emotional weight, Jeff responded with almost clinical clarity: he asked the doctor for a job. That move signaled that his path would run through science and problem-solving. In the end, that decision made him both a patient awaiting disease and a leading researcher working on treatments for the very condition he might carry.
Today Jeff is a key figure in a large project aimed at accelerating the development of highly precise therapies for multiple neurodegenerative diseases, including his own. He left a traditional academic career and his own lab to join the Brain Health Accelerator in Seattle at the Allen Institute — a hub for neuroscience research founded by Microsoft co‑founder Paul Allen. The initiative is a $400 million bet on a team-based approach using cutting-edge technologies, with $100 million coming from the Bezos family as strategic local philanthropy: Seattle is their hometown and Amazon’s base, and the investment aims to speed the development of treatments for neurodegenerative diseases while combining personal interest with support for the regional science ecosystem. “I want the ability to take developments and actually push them forward,” Jeff explains of his shift into a more collaborative, mission-driven role.
The Accelerator’s goal is to get a first experimental gene therapy into human clinical trials within five years. Unlike traditional academic labs that operate on long-term grants and publications, it is a platform of “catalytic resources”: it provides scientists with ready infrastructure, equipment and data access to rapidly test hypotheses and translate findings into clinical trials. The core idea is that years of basic brain research, which have mapped thousands of cell types and complex neural circuits, finally yield enough knowledge to create a new class of precision therapies. These genetic treatments will be designed to target only the specific cells and circuits where diseases like Huntington’s, Parkinson’s, Alzheimer’s and ALS begin. “Our motto is to take on huge problems, try to solve them with all our energy, and create catalytic resources for the scientific community,” says Ed Lane, a neuroscientist and director of the Accelerator. His approach, borrowing a culture of rapid iteration from the region’s tech companies, is a natural extension of Seattle’s innovative culture applied to biomedicine.
Jeff’s path into science was far from linear. He dropped out of school and joined the U.S. Army, with no family of scientists and no plans beyond a vague idea of a legal career. He and Megan had been married about six months when, on a visit home to Washington state, he learned his mother had Huntington’s disease. Looking back, he realized his grandmother had likely suffered the same illness, but the family had never discussed it seriously. Jeff’s deeply religious mother had reassured them that she had received a blessing at church and would not get sick.
Huntington’s disease slowly kills brain cells, causing jerky involuntary movements, unstable behavior and cognitive decline, typically beginning in one’s 30s or 40s. It is a dominant genetic disorder: a single mutant copy of the gene from one parent guarantees that symptoms will develop. While serving in Kosovo, Jeff began searching for information about the disease online and encountered grim stories and dubious “cures,” like shark cell injections that offered false hope. After leaving the Army, he and Megan moved to Vancouver — a city just 200 km from Seattle that would later play an important role in cross-border scientific collaboration: the distance allows for easy data exchange, joint genetic studies using shared population databases and coordination of clinical trials, creating a contiguous research corridor for studying neurodegenerative diseases. Returning to his studies, Jeff became fascinated with biology, which changed his sense of what life could hold.
“I didn’t have doctors or scientists in my family. I thought that was for some special people,” Jeff recalls of his early doubts. Nevertheless, he decided to take the Huntington’s mutation test, knowing the result would determine all his choices. When the test confirmed he carried expanded CAG repeats, his next step became clear: devote himself to finding a cure. In practice, that meant starting at the bottom in research labs and slowly building a career in Huntington’s disease science.
Jeff began studying Huntington’s in the lab of Michael Hayden, one of the world’s leading experts on the disease. He later did a postdoc at Harvard Medical School and established his own labs at Western Washington University in Bellingham and the University of Washington in Seattle. The University of Washington houses one of the world’s leading centers for Huntington’s research, including clinical trials and genetic studies, while Western Washington University contributes through training specialists and basic neuroscience research, particularly in neurophysiology and behavior. Together they form a talent and research pipeline for projects like the Brain Health Accelerator. Jeff’s research focused on mouse models of Huntington’s disease — work at once unglamorous and inspiring, allowing observation of how the disease unfolds in living organisms. The central problem is that the chain of repeating CAG letters in the HTT gene produces an abnormally long, error-prone version of the huntingtin protein that forms toxic clumps and elongates over a person’s lifetime.
Jeff inherited 42 CAG repeats from his mother — a number that very likely means symptoms will develop, turning abstract biology into a deeply personal matter. The consequences of the disease are forever etched in his memory because of his mother’s final days. A combination of other medical issues — a hospital-acquired infection and drug interactions — sped her decline and deepened her suffering.
Based on: This scientist learned he has a devastating brain disease. He set out to cure it.